Shares of Cardiff Oncology (CRDF) fell ~35% to reach a new 52-week low on Tuesday after the cancer drug developer said its chief executive officer and chief financial officer have both resigned from ...
Onvansertib cut the risk of death or disease progression by 62% versus standard of care, but analysts await more detailed ...
CEO Mark Erlander and CFO James Levine have stepped down as part of a leadership change necessary for Cardiff's transition to late-stage development, the company said Tuesday. Board member Mahi ...
Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results